Page 64 - Demo456

Movers & shakers
Shaker Spotlight
Mccann HealtH naMes
new President
as one of the most awarded healthcare communications networks continues to expand globally, McCann appoints Jim Joseph to President, North america. Joseph himself has led many awarded agencies and will be bringing
experience in managing global brands and agencies for sustained growth and innovation. he will now oversee all advertising and promotion agencies in the U.s. and Canada, as well as build and expand McCann’s growth team.
“I look forward to seeing the results of Jim’s expert leadership at McCann health North america,” said John Cahill, Global Ceo of McCann health. “his decades-long industry experience, investment in innovation, and talent will help continue the momentum we have been seeing in the region and push us even further towards raising the bar in delivering the best possible work for our clients.”
Joseph was previously Managing Director of saatchi & saatchi Wellness as well as author of the award-winning book and blog series The experience effect, about the impact that a compelling and consistent brand experience can have on customer loyalty and business results.
alexion aPPoints First
cHieF diversity oFFicer
Uzair Qadeer has been promoted to be the first Chief Diversity officer
at alexion Pharmaceuticals, where he will build a diversity, inclusion, and belonging (DI&B) strategy; foster relationships with key leaders,
communities, and organizations to create awareness
and advocacy for diversity and inclusion efforts; and advance a unique culture of belonging and diversity for the company’s patients and employees. Qadeer will be integral in the drug maker’s efforts to spread DI&B across employee programs, corporate social responsibility initiatives, culture efforts, and patient programs.
Ludwig hantson, PhD, Ceo, said in a statement, “establishing the Chief Diversity officer role at alexion is an important next step in our continued efforts to cultivate diversity, inclusion, and a unique sense of belonging at the company, all of which enhances our ability to deliver on our mission of transforming the lives of patients with rare diseases and devastating conditions.”
62 pm360 magazine / September 2020
arcutis Biotherapeutics
Patrick Burnett, MD, PhD, FAAD, has become Chief Medical officer of the immuno-dermatology biopharma company. he will
be helping arcutis advance its pipeline of four novel therapies and move their lead program
into clinical with his extensive knowledge of the clinical process of dermatology drug development.
aslan Pharmaceuticals
The immunology, oncology focused biopharma announced that Kenneth Kobayashi,
MD, has been appointed Chief Medical officer. Dr. kobayashi will be responsible for the global clinical development of asLaN’s pipeline, including the lead program, asLaN004, an atopic dermatitis antibody. he has spent 25 years in the dermatological drug development, clinical, and regulation space.
atea Pharmaceuticals
The infectious disease biotech tapped former abbvie executive Janet Hammond, MD, PhD, for its Chief Development officer
position. she joined shortly after atea received $215 million series
D financing for Phase 2 trial of its oral purine nucleotide prodrug aT-527 for people hospitalized with moderate cases of CovID-19. Dr. hammond will be trusted to lead development of the CovID drug as well as programs aimed at dengue, respiratory syncytial virus (rsv), and hepatitis C that have been delayed due to the pandemic.
calcium
The growing marketing agency welcomes Kate Shaughnessy, evP, head of Client
services to its executive team. shaughnessy has a history of transforming and retaining client relationships. she will lead the account service team and make it her focus to encourage creativity and collaboration in her new virtual office. she boasts 18 years of experience including time spent at agencies such as razorfish health and snow Companies.
instep Health
The healthcare marketer is making major additions to its leadership